The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

February 26, 2024

Study Completion Date

June 14, 2024

Conditions

Glabellar Frown Lines

Interventions

BIOLOGICAL

PROTOXIN

Clostridium botulinum toxin type A

Trial Locations (3)

Chung-Ang University Hospital, Seoul

Konkuk University Hospital, Seoul

Nowon Eulji Medical Center, Seoul

All Listed Sponsors

lead

Protox Inc.

INDUSTRY

NCT06124794 - The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter